Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Nat Rev Cancer. 2012 Mar 22;12(4):265–277. doi: 10.1038/nrc3258

Figure 6. DCs and cancer immunotherapy.

Figure 6

a | Random targeting of dendritic cells (DCs) in ‘endogenous’ vaccination results from in vivo antigen release owing to immunogenic cell death in response to chemotherapy, radiotherapy and immunomodulation approaches that are targeted at T cells. b | Vaccines can be based on ex vivo-generated tumour antigen-loaded DCs that are injected back into patients. c | Specific in vivo DC targeting with DC antibodies fused with antigens and with DC activators is shown. d | Targeting DCs in the tumour microenvironment to reprogramme pro-tumour inflammation towards tumour rejection is shown. MHC, major histocompatibility complex; TLR, Toll-like receptor.